{"id":"https://openalex.org/W7225228789","doi":"https://doi.org/10.3389/fphar.2026.1982274","title":"A tumor-responsive nanoplatform orchestrating multiplexed macrophage engagers and immune checkpoint blockade for triple-negative breast cancer immunotherapy","display_name":"A tumor-responsive nanoplatform orchestrating multiplexed macrophage engagers and immune checkpoint blockade for triple-negative breast cancer immunotherapy","publication_year":2026,"publication_date":"2026-11-04","ids":{"openalex":"https://openalex.org/W7225228789","doi":"https://doi.org/10.3389/fphar.2026.1982274"},"language":"en","primary_location":{"id":"doi:10.3389/fphar.2026.1982274","doi":"https://doi.org/10.3389/fphar.2026.1982274","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1982274","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1982274/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1982274/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5159592296","display_name":"Bo Xiang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210098607","display_name":"Jilin Province Tumor Hospital","ror":"https://ror.org/00vgek070","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210098607"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Bo Xiang","raw_affiliation_strings":["Department of Breast Surgery, Jilin Cancer Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Breast Surgery, Jilin Cancer Hospital","institution_ids":["https://openalex.org/I4210098607"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100338067","display_name":"Tao Liu","orcid":"https://orcid.org/0000-0001-6244-7316","observed_orcids":["https://orcid.org/0000-0001-6244-7316","https://orcid.org/0000-0002-8818-8313"]},"institutions":[{"id":"https://openalex.org/I4210098607","display_name":"Jilin Province Tumor Hospital","ror":"https://ror.org/00vgek070","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210098607"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Tao Liu","raw_affiliation_strings":["Department of Breast Surgery, Jilin Cancer Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Breast Surgery, Jilin Cancer Hospital","institution_ids":["https://openalex.org/I4210098607"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100391941","display_name":"Wei Wang","orcid":"https://orcid.org/0000-0002-3422-0402","observed_orcids":["https://orcid.org/0000-0002-3422-0402"]},"institutions":[{"id":"https://openalex.org/I4210098607","display_name":"Jilin Province Tumor Hospital","ror":"https://ror.org/00vgek070","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210098607"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Wei Wang","raw_affiliation_strings":["Department of Breast Surgery, Jilin Cancer Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Breast Surgery, Jilin Cancer Hospital","institution_ids":["https://openalex.org/I4210098607"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160713112","display_name":"Guiying Xu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210098607","display_name":"Jilin Province Tumor Hospital","ror":"https://ror.org/00vgek070","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210098607"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Guiying Xu","raw_affiliation_strings":["Department of Breast Surgery, Jilin Cancer Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Breast Surgery, Jilin Cancer Hospital","institution_ids":["https://openalex.org/I4210098607"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088004127","display_name":"Mingchong Liu","orcid":"https://orcid.org/0000-0001-8180-2379","observed_orcids":["https://orcid.org/0000-0001-8180-2379"]},"institutions":[{"id":"https://openalex.org/I116953780","display_name":"Tongji University","ror":"https://ror.org/03rc6as71","country_code":"CN","type":"education","lineage":["https://openalex.org/I116953780"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Mingchong Liu","raw_affiliation_strings":["School of Medicine, Tongji University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Medicine, Tongji University","institution_ids":["https://openalex.org/I116953780"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5067374817","display_name":"Duo Xu","orcid":"https://orcid.org/0000-0002-2445-5662","observed_orcids":["https://orcid.org/0000-0002-2445-5662","https://orcid.org/0009-0008-7231-1605","https://orcid.org/0009-0008-8930-9317"]},"institutions":[{"id":"https://openalex.org/I4210098607","display_name":"Jilin Province Tumor Hospital","ror":"https://ror.org/00vgek070","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210098607"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Duo Xu","raw_affiliation_strings":["Department of Breast Surgery, Jilin Cancer Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Breast Surgery, Jilin Cancer Hospital","institution_ids":["https://openalex.org/I4210098607"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5067374817"],"corresponding_institution_ids":["https://openalex.org/I4210098607"],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.83547447,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"17","issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.5259000062942505,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.5259000062942505,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11313","display_name":"Immune cells in cancer","score":0.1746000051498413,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.13349999487400055,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.9990000128746033},{"id":"https://openalex.org/keywords/tumor-associated-macrophages","display_name":"tumor-associated macrophages","score":0.8389999866485596},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.8600000143051147},{"id":"https://openalex.org/keywords/pd-l1-inhibitors","display_name":"PD-L1 inhibitors","score":0.8949999809265137},{"id":"https://openalex.org/keywords/lipid-nanoparticles","display_name":"lipid nanoparticles","score":0.7409999966621399},{"id":"https://openalex.org/keywords/egfr","display_name":"EGFR","score":0.6480000019073486},{"id":"https://openalex.org/keywords/trop2","display_name":"TROP2","score":0.9990000128746033},{"id":"https://openalex.org/keywords/glutathione-responsive-drug-release","display_name":"glutathione-responsive release","score":0.7720000147819519},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.734000027179718},{"id":"https://openalex.org/keywords/m1-macrophage-polarization","display_name":"M1 macrophage polarization","score":0.8159999847412109},{"id":"https://openalex.org/keywords/pi3k-akt-mtor-pathway","display_name":"PI3K/AKT/mTOR pathway","score":0.8989999890327454},{"id":"https://openalex.org/keywords/myeloid-derived-suppressor-cells","display_name":"myeloid-derived suppressor cells","score":0.8859999775886536},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.5680000185966492}],"concepts":[{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5525000095367432},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.541700005531311},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5224000215530396},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.5113999843597412},{"id":"https://openalex.org/C136449434","wikidata":"https://www.wikidata.org/wiki/Q428253","display_name":"Innate immune system","level":3,"score":0.4943000078201294},{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.49230000376701355},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.492000013589859},{"id":"https://openalex.org/C2780110267","wikidata":"https://www.wikidata.org/wiki/Q7843332","display_name":"Triple-negative breast cancer","level":4,"score":0.4885999858379364},{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.484499990940094},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.48100000619888306},{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.43059998750686646},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.4255000054836273},{"id":"https://openalex.org/C2779244956","wikidata":"https://www.wikidata.org/wiki/Q184204","display_name":"Macrophage","level":3,"score":0.3971000015735626},{"id":"https://openalex.org/C127561419","wikidata":"https://www.wikidata.org/wiki/Q224527","display_name":"Downregulation and upregulation","level":3,"score":0.3903999924659729},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3898000121116638},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3889999985694885},{"id":"https://openalex.org/C2778017598","wikidata":"https://www.wikidata.org/wiki/Q7390325","display_name":"SIGLEC","level":3,"score":0.38769999146461487},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.350600004196167},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.3197999894618988},{"id":"https://openalex.org/C193419808","wikidata":"https://www.wikidata.org/wiki/Q1645075","display_name":"Acquired immune system","level":3,"score":0.3154999911785126},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.29750001430511475},{"id":"https://openalex.org/C18150654","wikidata":"https://www.wikidata.org/wiki/Q17153796","display_name":"Nanocarriers","level":3,"score":0.29679998755455017},{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.28600001335144043},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.27810001373291016},{"id":"https://openalex.org/C102747710","wikidata":"https://www.wikidata.org/wiki/Q824237","display_name":"Endosome","level":3,"score":0.27639999985694885},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2761000096797943},{"id":"https://openalex.org/C179185449","wikidata":"https://www.wikidata.org/wiki/Q219699","display_name":"Suppressor","level":3,"score":0.27480000257492065},{"id":"https://openalex.org/C2776914184","wikidata":"https://www.wikidata.org/wiki/Q101991","display_name":"Inflammation","level":2,"score":0.2651999890804291},{"id":"https://openalex.org/C96232424","wikidata":"https://www.wikidata.org/wiki/Q4118072","display_name":"Cancer cell","level":3,"score":0.25949999690055847},{"id":"https://openalex.org/C54174078","wikidata":"https://www.wikidata.org/wiki/Q3197188","display_name":"Kinome","level":3,"score":0.2533000111579895},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.2529999911785126}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.3389/fphar.2026.1982274","doi":"https://doi.org/10.3389/fphar.2026.1982274","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1982274","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1982274/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.3389/fphar.2026.1982274","doi":"https://doi.org/10.3389/fphar.2026.1982274","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1982274","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1982274/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320322174","display_name":"People's Government of Jilin Province","ror":"https://ror.org/02fzqav45"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7225228789.pdf","grobid_xml":"https://content.openalex.org/works/W7225228789.grobid-xml"},"referenced_works_count":33,"referenced_works":["https://openalex.org/W4297238081","https://openalex.org/W4402048589","https://openalex.org/W4405356254","https://openalex.org/W4406071944","https://openalex.org/W4406962261","https://openalex.org/W4409107933","https://openalex.org/W4409318889","https://openalex.org/W4410948767","https://openalex.org/W4411698841","https://openalex.org/W4412091904","https://openalex.org/W4412583716","https://openalex.org/W4413296734","https://openalex.org/W4416334709","https://openalex.org/W4416604105","https://openalex.org/W7118713863","https://openalex.org/W7124991947","https://openalex.org/W7126234313","https://openalex.org/W7126234784","https://openalex.org/W7130847915","https://openalex.org/W7153546806","https://openalex.org/W7161109633","https://openalex.org/W7161975425","https://openalex.org/W7162326868","https://openalex.org/W7164058137","https://openalex.org/W7164931819","https://openalex.org/W7165049114","https://openalex.org/W7166054630","https://openalex.org/W7167248391","https://openalex.org/W7169125137","https://openalex.org/W7169860712","https://openalex.org/W7203442878","https://openalex.org/W7204176898","https://openalex.org/W7204252937"],"related_works":["https://openalex.org/W4416538726","https://openalex.org/W7125769282","https://openalex.org/W4319216222","https://openalex.org/W4388521068","https://openalex.org/W4411377394","https://openalex.org/W2767395146","https://openalex.org/W4386800313","https://openalex.org/W2592596865","https://openalex.org/W7222185375","https://openalex.org/W3214162657"],"abstract_inverted_index":{"Introduction":[0],"Triple\u2010negative":[1],"breast":[2],"cancer":[3],"(TNBC)":[4],"remains":[5],"a":[6,43,96,111,143,208,232],"formidable":[7],"clinical":[8],"challenge":[9],"due":[10],"to":[11,53,101,117,169],"its":[12],"profound":[13],"inter\u2010":[14],"and":[15,18,57,80,151,182,237],"intra\u2010tumoral":[16],"heterogeneity":[17],"highly":[19,148],"immunosuppressive":[20,188,238],"tumor":[21,205],"microenvironment":[22],"(TME),":[23],"which":[24],"severely":[25],"limit":[26],"the":[27,107,118,128,158,172,175,214],"efficacy":[28],"of":[29,89,161,178,226],"standard":[30],"immune":[31,167],"checkpoint":[32],"blockade":[33],"(ICB)":[34],"therapies.":[35],"To":[36],"overcome":[37],"these":[38,220],"multifactorial":[39],"barriers,":[40],"we":[41],"engineered":[42],"dual\u2010responsive,":[44],"targeted":[45],"lipid":[46,99],"nanoparticle":[47],"platform,":[48],"denoted":[49],"as":[50,231],"R\u2010DCPA\u2010GPL\u2010LNP@mET,":[51],"designed":[52],"holistically":[54],"orchestrate":[55],"innate":[56,166],"adaptive":[58],"anti\u2010tumor":[59],"immunity.":[60],"Methods":[61],"This":[62],"multifunctional":[63],"nanoplatform":[64,230],"co-delivers":[65],"multiplexed":[66],"mRNAs":[67],"encoding":[68],"bispecific":[69,130],"macrophage":[70],"engagers":[71,131],"that":[72],"simultaneously":[73],"target":[74],"Epidermal":[75],"Growth":[76],"Factor":[77],"Receptor":[78],"(EGFR)":[79],"Trophoblast":[81],"cell-surface":[82],"antigen":[83],"2":[84],"(TROP2),":[85],"ensuring":[86],"comprehensive":[87],"engagement":[88],"heterogeneous":[90,236],"TNBC":[91,138,196],"cells.":[92,191],"The":[93],"nanocarrier":[94],"utilizes":[95],"pH-responsive":[97],"charge-reversal":[98],"(DCPA)":[100],"accelerate":[102],"robust":[103],"endosomal":[104],"escape":[105],"in":[106],"acidic":[108],"TME,":[109,173],"alongside":[110],"glutathione":[112],"(GSH)-cleavable":[113],"anti-PD-L1":[114,162],"antibody":[115],"tethered":[116],"surface":[119],"for":[120,235],"tumor-selective":[121],"ICB":[122],"release.":[123],"Results":[124],"Upon":[125],"systemic":[126],"administration,":[127],"translated":[129],"physically":[132],"bridge":[133],"tumor-associated":[134],"macrophages":[135],"(TAMs)":[136],"with":[137,164,207],"cells,":[139],"reprograming":[140],"TAMs":[141],"toward":[142],"tumoricidal":[144],"M1":[145],"phenotype,":[146],"triggering":[147],"efficient":[149],"phagocytosis,":[150],"neutralizing":[152],"oncogenic":[153],"PI3K/AKT/mTOR":[154],"signaling":[155],"pathways.":[156],"Concurrently,":[157],"localized":[159],"release":[160],"synergizes":[163],"this":[165,199,227],"activation":[168],"profoundly":[170],"remodel":[171],"driving":[174],"extensive":[176],"infiltration":[177],"cytotoxic":[179],"T":[180],"lymphocytes":[181],"Natural":[183],"Killer":[184],"cells":[185],"while":[186],"depleting":[187],"myeloid-derived":[189],"suppressor":[190],"In":[192],"an":[193],"orthotopic":[194],"4T1":[195],"murine":[197],"model,":[198],"multiplexed,":[200,228],"spatiotemporal":[201],"intervention":[202],"induced":[203],"marked":[204],"regression":[206],"favorable":[209],"preliminary":[210],"safety":[211],"profile":[212],"over":[213],"22-day":[215],"observation":[216],"period.":[217],"Discussion":[218],"Collectively,":[219],"preclinical":[221],"findings":[222],"support":[223],"further":[224],"development":[225],"dual-responsive":[229],"promising":[233],"strategy":[234],"solid":[239],"tumors.":[240]},"counts_by_year":[],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2026-11-05T00:00:00"}